---
source_path: F2505A-PDF-ENG.md
pages: n/a-n/a
chunk_id: e8c37b5c2e06045cc63cc29cd9e56806161f2e91
title: F2505A-PDF-ENG
---
# likely cease or limit experimentation.

Is there a strategic ﬁt? Roche advises startups to consider the investor’s

preferred exit strategy, whether it be acquisition, IPO, or allowing

the startup to keep growing as a proﬁtable, stand-alone company.

The investor’s ultimate goals can signiﬁcantly impact the startup’s

growth trajectory and operational decisions. Investors seeking a near-

term IPO are more likely to push for quicker results over constant
